NANOGROUP S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.02 PLN | -0.49% |
|
-0.97% | +9.91% |
| 2023 | NanoGroup S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
| 2023 | NanoGroup S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2021 | 492K 122K 167K | Sales 2022 | 140K 34.68K 47.38K | Capitalization | 20.83M 5.18M 7.07M |
|---|---|---|---|---|---|
| Net income 2021 | -10M -2.49M -3.4M | Net income 2022 | - 0 0 | EV / Sales 2021 | 115 x |
| Net cash position 2021 | 3.71M 923K 1.26M | Net cash position 2022 * | - 0 0 | EV / Sales 2022 | 149 x |
| P/E ratio 2021 |
-6.01
x | P/E ratio 2022 |
-24.8
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.19% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.49% | ||
| 1 week | -0.97% | ||
| Current month | -0.97% | ||
| 1 month | -0.97% | ||
| 3 months | +6.92% | ||
| 6 months | +5.15% | ||
| Current year | +9.91% |
1 week
1.00
1.05
1 month
1.001.05
Current year
0.891.18
1 year
0.851.30
3 years
0.856.10
5 years
0.8513.00
10 years
0.8513.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 58 | 16-12-11 | |
| Chief Executive Officer | 48 | 17-02-08 | |
Anna Redwan
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 61 | 21-06-27 | |
| Director/Board Member | 72 | 17-02-08 | |
| Director/Board Member | 54 | 17-04-18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1.02 | -0.49% | 105,268 |
| 24-04-25 | 1.025 | +0.99% | 61,980 |
| 24-04-24 | 1.015 | +0.50% | 404,603 |
| 24-04-23 | 1.01 | -0.98% | 11,441 |
| 24-04-22 | 1.02 | -0.97% | 75,040 |
Delayed Quote Warsaw S.E., April 26, 2024 at 11:55 am
More quotes
Nanogroup SA is a Poland-based company engaged in the biotechnology sector. The Company focuses on the investment in, as well as development of advanced biotechnological projects in the areas of cancer prevention, early diagnosis, targeted cancer therapies and ontological rehabilitation. Its projects portfolio includes NanoVelos, which is responsible for the creation of drug delivery system for proven oncologic medicines to optimize their performance; NanoSanguis, which develops artificial blood to keep alive patients wounded in accidents, as well as a system, named Organ farm, to preserve human organs ex vivo, and NanoThea, which is dedicated to technology that detects cancer cells in early stage.
| 1st Jan change | Capi. | |
|---|---|---|
| +9.91% | 5.06M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- NNG Stock
